公开(公告)号：US06317093B1

公开(公告)日：2001-11-13

申请号：US09635937

申请日：2000-08-10

申请人： Joel Harris

发明人： Joel Harris

IPC分类号： H01Q300

CPC分类号： H01Q19/19 ,  G01S3/38 ,  H01Q1/1257 ,  H01Q3/08 ,  H01Q19/132

摘要： An antenna pointing system automatically aligns an antenna with a geo-synchronous satellite using a Ku band signal, which has a relatively broad bandwidth, with sufficient accuracy for Ka band signal transmission, which has a relatively narrow bandwidth. Initially, the antenna is pointed at the selected satellite so as to receive the Ku band signal. The system obtains a series of signal strength readings over a predetermined azimuth (or elevation) region, such as plus/minus two degrees, from which a new peak location is selected. Signal strength data is then obtained over a predetermined elevation (or azimuth) region. Another signal peak location is selected based on the elevation data. Azimuth and elevation data are alternately collected for refining the peak of the Ku signal so as to optimize Ka signal transmission capability.

摘要翻译： 天线指向系统使用具有相对宽的带宽的Ku波段信号自动对准天线与地球同步卫星，对于具有相对较窄带宽的Ka波段信号传输具有足够的精度。 最初，天线指向所选择的卫星，以便接收Ku波段信号。 该系统在预定的方位角（或高度）区域上获得一系列信号强度读数，例如正/负两度，从中选择新的峰值位置。 然后在预定的高度（或方位））区域获得信号强度数据。 基于高程数据选择另一个信号峰值位置。 交替收集方位角和高程数据，以便优化Ku信号的峰值，从而优化Ka信号传输能力。

公开(公告)号：US20160009696A1

公开(公告)日：2016-01-14

申请号：US14772290

申请日：2014-02-27

申请人： Michael MILLER ,  Kallol BASU ,  Duane DEMONG ,  Jack SCOTT ,  Wei LI ,  Joel HARRIS ,  Andrew STAMFORD ,  Marc POIRIER ,  Paul TEMPEST ,  MERCK SHARP & DOHME CORP.

发明人： Michael Miller ,  Kallol Basu ,  Duane DeMong ,  Jack Scott ,  Wei Li ,  Joel Harris ,  Andrew Stamford ,  Marc Poirier ,  Paul Tempest

IPC分类号： C07D403/14 ,  C07D401/14 ,  C07D491/107 ,  C07D417/14 ,  C07D471/10 ,  C07D413/14 ,  C07D498/08

CPC分类号： C07D403/14 ,  A61K31/505 ,  A61K31/506 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10 ,  C07D491/107 ,  C07D498/08

摘要： The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

公开(公告)号：US20080076751A1

公开(公告)日：2008-03-27

申请号：US11854754

申请日：2007-09-13

申请人： Robert Aslanian ,  Chad Bennett ,  Duane Burnett ,  Tin-Yau Chan ,  Eugenia Kiselgof ,  Chad Knutson ,  Joel Harris ,  Brian McKittrick ,  Anandan Palani ,  Elizabeth Smith ,  Henry Vaccaro ,  Dong Xiao ,  Hyunjin Kim

发明人： Robert Aslanian ,  Chad Bennett ,  Duane Burnett ,  Tin-Yau Chan ,  Eugenia Kiselgof ,  Chad Knutson ,  Joel Harris ,  Brian McKittrick ,  Anandan Palani ,  Elizabeth Smith ,  Henry Vaccaro ,  Dong Xiao ,  Hyunjin Kim

IPC分类号： A61K31/397 ,  A61P25/04 ,  A61P3/00 ,  C07D471/10

CPC分类号： C07D471/10

摘要： The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.

摘要翻译： 本发明涉及氮杂环丁酮衍生物，包含氮杂环丁酮衍生物的组合物和用于治疗或预防脂质代谢紊乱，疼痛，糖尿病，血管病症，脱髓鞘或非酒精性脂肪性肝病的方法，包括向患者施用有效量的 氮杂环丁酮衍生物。

公开(公告)号：US20050239795A1

公开(公告)日：2005-10-27

申请号：US11108916

申请日：2005-04-19

申请人： Bernard Neustadt ,  Jinsong Hao ,  Hong Liu ,  Craig Boyle ,  Samuel Chackalamannil ,  Unmesh Shah ,  Andrew Stamford ,  Joel Harris

发明人： Bernard Neustadt ,  Jinsong Hao ,  Hong Liu ,  Craig Boyle ,  Samuel Chackalamannil ,  Unmesh Shah ,  Andrew Stamford ,  Joel Harris

IPC分类号： A61K31/519 ,  C07D487/14

CPC分类号： C07D487/14

摘要： Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

摘要翻译： 具有结构式I的化合物或其药学上可接受的盐，其中R是任选取代的苯基，呋喃基，噻吩基，吡啶基，吡啶基N-氧化物，恶唑基或吡咯基，或环烯基R 1， R 3，R 3，R 4和R 5是H，烷基或烷氧基烷基; 和Z是任选取代的芳基或杂芳基。 还公开了式I化合物在治疗中枢神经系统疾病，特别是帕金森病中单独使用或与用于治疗帕金森病的其它药物组合的用途，以及包含它们的药物组合物的用途。